ClinicalTrials.gg
RecruitingNCT03997110RAPPALUpdated Feb 17, 2026

Palliative Radiation for Advanced Cervical Cancer

An interventional study of Short course palliative radiation. and Long course palliative treatment. in Cervical Cancer, sponsored by Tata Memorial Hospital. Recruiting at 1 site in India. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Tata Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Tata Memorial Hospital.

Planned enrollment
11th of 17
230 · median 316
Started
2020
the only one that year
No phase
10 of 27
2 open now
Registered
19th of 27
by date

Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2020, is one of 10 with no phase, and was the 19th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, or all of them as a file.
02

Study summary

The present study is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer.

Read the detailed description

This is a prospective randomised open label Phase III study. This study is is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer. The primary objective of the study is pain relief in the experimental arm as compared to the control arm from treatment until 12 weeks from start of radiotherapy. Patients with locally advanced cervical cancer (Stage III B-IV A) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation, patients whose anticipated survival is less than 12 months will be included in the study. Patients with distant metastasis and those with retroviral disease will be excluded from the study. The patients will be randomised in one of the two groups:

Arm A : Control Arm - Long Course Palliative Radiation: Week 1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week 4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week 7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients which will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity.

Arm B: Experimental arm- Short Course Palliative radiation. Week 1: Patients will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.There is no potential direct benefit to the study participants. However the aim is to use the available information to evolve treatment in future. The variables to be estimated are pain relief, disease related symptoms relief, CTCAE Toxicity, Quality of Life,overall survival and compliance to therapy.

03

Conditions studied

  • Cervical Cancer

Keywords

  • Cervical Cancer
  • Palliative treatment
  • Radiation Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Locally advanced cervical cancer (Stage IIIB-IVA) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation due to the following reasons:

    • Very large volume hard fixed disease infiltrating pelvic wall muscles and ligaments on clinical examination also classified clinically as "frozen pelvis" wherein curative intent treatment is not envisaged or feasible.
    • Fistulous communication between tumour growth and rectum and bladder >2x2 cm in size (as judged by cystoscopy for bladder infiltration or clinical or proctosigmoidoscopy examination for rectal/sigmoid infiltration) wherein radical intent treatment is not intended or feasible and patient is not a candidate for pelvic exenteration.
    • Deranged renal parameters as measured by Serum Creatinine >3 mg/dl wherein diversion nephrostomy is not planned by the multidisciplinary team due to anticipated poor clinical outcomes.Furthermore concurrence for palliative intent radiotherapy should be corroborated by 2 staff radiation oncologists.
  2. Moderate to Severe Pain on Numerical Rating Score (Score 4 or higher).
  3. Anticipated survival \< 12 months.
  4. Patients with stage IVB with local disease extent as described in section 1 but systemic chemotherapy is not possible either due to deranged renal function or anticipated poor tolerance.

Exclusion criteria

Exclusion Criteria:

  1. Patients with distant needing upfront systemic therapy.
  2. Presence of retroviral disease
  3. Non-compliant for follow up.
  4. Expected survival \<3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Active comparator
    Arm A Or Control Arm- Long course palliative treatment.

    Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity

    Radiation: Long course palliative treatment.

  • Experimental
    Arm B or Experimental Arm-Short course palliative radiation.

    Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.

    Radiation: Short course palliative radiation.

Interventions

  • RadiationShort course palliative radiation.

    Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.

  • RadiationLong course palliative treatment.

    Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity

06

What researchers measure

Primary outcomes

  1. Pain Relief (Numerical pain rating scale will be used)

    Pain relief in the experimental arm as compared to the control arm from treatment until 12 weeks from start of radiotherapy will be assessed. Pain relief will be assessed at 12 weeks from start of radiotherapy. (Pain has been chosen as the primary endpoint as it is the primary complaint in almost 2/3 rd of patients. Numerical pain rating scale has been chosen for objective pain assessment as it is easy to use and has been proven to be a reliable tool in multiple studies. Pain score will be documented on 11-scale numerical pain rating scale (NRS) and qualified into one of the following categories: i)Pain score of 0-3- No to mild pain ii)Pain score 4-7- Moderate pain iii)Pain score \>7- Severe pain

    Time frame: 1 week, 4 week, 7 week, 12 weeks

Secondary outcomes

  1. Pain Relief (Numerical pain rating scale will be used)

    Pain relief at 6, 9 and 12 month of follow up. Pain score will be documented on 11-scale numerical pain rating scale (NRS) and qualified into one of the following categories: i) Pain score of 0-3- No to mild pain ii) Pain score 4-7- Moderate pain iii) Pain score \>7- Severe pain

    Time frame: 6 months, 9 months, 12 months

  2. Presence or absence of vaginal bleeding and/or discharge and relief in vaginal bleeding (as reported by the patient)

    Complete relief in vaginal bleeding and non-infectious discharge will be documented at 12 weeks from start of RT as reported by the patient. Although vaginal bleeding and discharge are also major presenting complaints, there is no standardized objective scale or criteria for measuring these in cancer patients. Vaginal discharge if present will be qualified as infectious or non-infectious. Infectious vaginal discharge will warrant antibiotic treatment.

    Time frame: 1 week,4 week,7week,12 weeks

  3. Change in use of analgesics (WHO ladder)

    Change in use of analgesics by either dose adjustment or stepping up/down on the WHO ladder at 12 weeks.This will also be recorded at each clinical follow up.

    Time frame: 12 weeks, 3 month, 9 month, 12 month

  4. Compliance to therapy

    Response of local disease will be assessed clinically at end of treatment and on every follow up. Response to RT will be determined on follow-up at 7 and 12 weeks in both the arms and phone call interviews when necessary for completeness in patients with poor compliance to follow up.

    Time frame: 7 week,12 week, 3 month, 9 month, 12 month

  5. Quality of Life using EORTC QLQC30 questionnaires

    Quality of Life using EORTC QLQC 30 questionnaire (European Organisation for Research \& Treatment of Cancer - Quality of Life Questionnaire of Cancer patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up. Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4. 1 will be considered as better outcome \& 4 will be considered as worst outcome.

    Time frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up.

  6. Quality of Life using EORTC QLQC-15 Pall questionnaires

    Quality of Life using EORTC QLQC-15 Pall (European Organisation for Research \& Treatment of Cancer - Quality of Life Questionnaire in Palliative Cancer care patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up. Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4. 1 will be considered as better outcome \& 4 will be considered as worst outcome.

    Time frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up.

  7. Quality of Life using Cx-24 questionnaires

    Quality of Life using Cx-24 questionnaires (European Organisation for Research \& Treatment of Cancer - Quality of Life Questionnaire of Cervical cancer patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up. Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4. 1 will be considered as better outcome \& 4 will be considered as worst outcome.

    Time frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up.

  8. Acute gastrointestinal and genitourinary toxicities

    Acute gastrointestinal and genitourinary toxicities using CTCAE ver4.0 grading will be measured within 90 days of Radiotherapy.

    Time frame: Within 90 days of Radiotherapy

  9. Late gastrointestinal and genitourinary toxicities

    Late gastrointestinal and genitourinary toxicities using CTCAE 4.0 grading will be measured after 90 days of Radiotherapy.

    Time frame: After 90 days of Radiotherapy

  10. Overall survival, defined as time from randomization until death due to any cause.

    Overall survival, defined as time from randomization until death due to any cause.

    Time frame: 1 year

  11. Patterns of terminal event (Due to local relapse or Distant Metastasis)

    Events leading to death will be determined by telephonic interview of the relatives at 3, 6, 9 or 12 months, as applicable to find out the terminal cause of death.

    Time frame: By telephonic interview of the relatives at 3, 6, 9 or 12 months, as applicable

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jul 2026, 72 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 72 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2019
First posted
Jun 25, 2019
StartActual
Jun 19, 2020
Primary completionEst.
Jul 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03997110
Lead sponsor
Tata Memorial Hospital
Collaborators
Tata Memorial Centre
Responsible party
Supriya Sastri (chopra) (Professor, Tata Memorial Hospital) — Principal investigator
First posted
Jun 25, 2019
Start date
Jun 19, 2020
Primary completion
Jul 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Supriya Chopra
Contact
supriyasastri@gmail.com
02227405000 ext. 5113
TMH Gyn DMG TMC
Contact
gwg.tmc@gmail.com
02224177000 ext. 6038
Supriya Sastri
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion